29
Views
4
CrossRef citations to date
0
Altmetric
Review

Analysis of patent applications relating to peroxisome proliferator-activated receptor (PPAR) ligands in 2004

Pages 1521-1530 | Published online: 28 Oct 2005
 

Abstract

Molecular pharmacological evidence that metabolic nuclear receptor peroxisome proliferator-activated receptors (PPARs) act as master regulators of lipid, lipoprotein and glucose homeostasis, in combination with the timely identification of fibrates and glitazones as selective PPARα and PPARγ agonists, and the rapid development of the parallel high-throughput screening (HTS) methods to evaluate activity towards PPAR subtypes (PPARα, PPARδ and PPARγ), has provided an opportunity to develop novel subtype-selective PPAR ligands. This review summarises patent applications disclosing medicinal-chemical strategies to identify new PPAR ligands during 2004. The historical development of PPAR ligands is also reviewed briefly to help to understand the detailed structure–activity relationships (SAR) and the interaction between ligands and PPARs. Current developments are expected to lead to novel therapeutic choices for the treatment of altered metabolic homeostasis, such as dyslipidaemia, diabetes and obesity.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.